Dengue Vaccines Market Poised for Rapid Growth, Expected to Reach USD 1603.7 Million in 2033 at a 12.9% of CAGR

The dengue vaccines market is set for strong growth, with an estimated valuation of US$ 474.8 million in 2023. The demand for dengue vaccines is projected to surge, with the market expected to grow at an impressive CAGR of 12.9% in terms of sales volume (units) over the forecast period.

Dengue vaccine development has entered a crucial phase, with several pharmaceutical giants expected to announce the results of extensive clinical trials that have been underway over the past decade. This influx of new data is anticipated to broaden the available options for dengue vaccination, breaking the current market monopoly held by Denvaxia®, the existing vaccine.

Dengue vaccine development has entered an important stage of its lifecycle – with a host of pharmaceutical giants expected to present the results of their extensive clinical trials initiated in the past decade or half-a-decade. The future availability of various alternatives is likely to break the monopoly of the existing Denvaxia® vaccine.

A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering new vaccine formulations. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as the presence of reputed regional pharmaceutical giants.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for dengue vaccines. The report tracks the global sales of dengue vaccines in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the healthcare industry in general, and dengue vaccines in particular.

Market Insights:

• Market Valuation: The global dengue vaccines market is forecasted to reach US$ 474.8 million in 2023.
• CAGR: The market is expected to experience a CAGR of 12.9% by sales in volume over the next decade.
• Clinical Trials & Innovation: Ongoing clinical trials by leading pharmaceutical companies are expected to diversify the dengue vaccine options, enhancing the market’s growth potential.
• Monopoly Breakthrough: The future availability of alternative vaccines could reduce reliance on the current Denvaxia® vaccine, encouraging more competitive pricing and wider accessibility.

As the landscape of dengue vaccination evolves, the market is likely to see an increase in both public and private investments, driving the availability of more effective and affordable vaccines. The expected influx of new products will open new opportunities in the global healthcare market, positioning the dengue vaccines market for robust growth in the years to come.

Competitive Landscape

Conducting clinical trials to develop multiple vaccine candidates remains the core expansion strategy of the aforementioned manufacturers. To enable this, market players are effectively leveraging strategic partnerships with major pharmaceutical corporations or research institutes, mergers & acquisitions, and capacity expansion initiatives.

• Sanofi Pasteur is the most prominent dengue vaccine manufacturer, currently offering the Dengvaxia®, a tetravalent dengue vaccine that is highly effective for preventing outbreaks resulting from all four dengue virus serotypes in preadolescents, adolescents, and adults, aged 9 to 45 years. The vaccine was approved after an extensive clinical development program spanning 40,000 people across 15 countries.
• In 2018, Merck & Co. collaborated with Instituto Butantan, Sao Paulo, Brazil, a non-profit producer of immunobiological products to develop vaccines to protect against the dengue virus. The partnership was aimed at developing live attenuated tetravalent vaccines (LATV). In addition, the institute also initiated its Phase 3 clinical trials for the TV003 vaccine candidate.
• In March 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), currently under investigation for preventing any outbreaks in individuals aged 4 to 60. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand through 2021.
• Takeda reported in May 2023 that their dengue vaccine QDENGA® has gained various approvals, such as one in March 2023 from Brazil’s National Health Surveillance Agency for use in persons aged 4 to 60 years to protect against all four serotypes.
• According to reports in Buenos Aires in April 2023, Argentine health officials authorized the consumption of a Japanese dengue vaccine that must be provided in two dosages three months intervals.

Key Companies Profiled

• Sanofi Pasteur Limited
• Takeda Pharmaceutical Company Limited
• Merck & Co. Inc.
• GlaxoSmithKline Plc.
• GeneOne Life Science Inc.
• Medigen Vaccine Biologics Corporation
• Panacea Biotec Limited
• Sun Pharmaceutical Industries Ltd
• Serum Institute of India Pvt. Ltd.
• Biological E Ltd.

Grab Your Complete Report Instantly

Key Segments Covered

Product:

• CYD-TDV (Dengvaxia)

End-User:

• Hospitals
• Government Institutes
• Non-governmental Organizations (NGOs)

Region:

• North America (USA and Canada)
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube